HK1198125A1 - Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy - Google Patents

Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy

Info

Publication number
HK1198125A1
HK1198125A1 HK14111635.2A HK14111635A HK1198125A1 HK 1198125 A1 HK1198125 A1 HK 1198125A1 HK 14111635 A HK14111635 A HK 14111635A HK 1198125 A1 HK1198125 A1 HK 1198125A1
Authority
HK
Hong Kong
Prior art keywords
predicting
efficacy
methods
cardiovascular diseases
treating cardiovascular
Prior art date
Application number
HK14111635.2A
Other languages
English (en)
Chinese (zh)
Inventor
James V Snider
Robert W Gerwien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198125A1 publication Critical patent/HK1198125A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
HK14111635.2A 2011-07-18 2014-11-18 Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy HK1198125A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508923P 2011-07-18 2011-07-18
US201161509359P 2011-07-19 2011-07-19
PCT/US2012/047238 WO2013012945A1 (en) 2011-07-18 2012-07-18 Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy

Publications (1)

Publication Number Publication Date
HK1198125A1 true HK1198125A1 (en) 2015-03-13

Family

ID=47558450

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111635.2A HK1198125A1 (en) 2011-07-18 2014-11-18 Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy

Country Status (13)

Country Link
US (5) US8748110B2 (de)
EP (2) EP3173093B1 (de)
JP (2) JP6134316B2 (de)
CN (2) CN103796669B (de)
AU (2) AU2012284039B2 (de)
BR (1) BR112014001283A2 (de)
CA (1) CA2842072A1 (de)
DK (1) DK2734222T3 (de)
ES (1) ES2611403T3 (de)
HK (1) HK1198125A1 (de)
MX (1) MX351428B (de)
PL (1) PL2734222T3 (de)
WO (1) WO2013012945A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
ES2646142T3 (es) 2006-04-24 2017-12-12 Critical Care Diagnostics, Inc. Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2
WO2007143295A2 (en) * 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2021796T3 (da) 2006-05-01 2012-05-29 Critical Care Diagnostics Inc Diagnose af hjerte-kar-sygdom
DK2019965T3 (en) * 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
SI2827152T1 (sl) 2008-04-18 2016-10-28 Critical Care Diagnostics,Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
RU2625014C2 (ru) 2010-04-09 2017-07-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
EP3434260A1 (de) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Verfahren zur behandlung oder vorhersage des risikos des ereignisses von ventrikulärer tachyarrhythmie
RU2019107598A (ru) 2012-08-16 2019-03-28 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
RU2015110054A (ru) 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
CN104017057B (zh) * 2014-06-27 2016-08-24 榆林市第一医院 一种st2蛋白抑制剂多肽及其应用
CN104017056B (zh) * 2014-06-27 2016-08-17 国科戎安生物科技（北京）有限公司 St2蛋白抑制剂多肽及其应用
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN107109494B (zh) 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN105259353B (zh) * 2015-10-15 2017-03-22 北京市心肺血管疾病研究所 一种主动脉瘤和/或主动脉夹层患者血液中可溶性st2的检测试剂盒及检测方法
WO2017179699A1 (ja) * 2016-04-15 2017-10-19 オムロン株式会社 生体情報分析装置、システム、及び、プログラム
EP3446124A1 (de) * 2016-04-18 2019-02-27 Roche Diagnostics GmbH Lösliche st2 zur identifizierung von progressoren von lvh in der gesamtbevölkerung
CN108982871B (zh) * 2018-07-19 2021-09-24 北京市心肺血管疾病研究所 血清sST2在小儿扩张型心肌病预后中的应用
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
RU2741195C1 (ru) * 2020-03-27 2021-01-22 Государственное бюджетное учреждение здравоохранения Нижегородской области "Нижегородская областная клиническая больница им. Н.А. Семашко" Способ прогнозирования ургентных сердечно-сосудистых осложнений при остром коронарном синдроме у больных с онкологическим заболеванием в анамнезе

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
JPS533020A (en) 1976-06-29 1978-01-12 Matsushita Electric Ind Co Ltd Static picture reception unit
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
JPS5911218U (ja) 1982-07-14 1984-01-24 松下電器産業株式会社 燃焼器
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4772684A (en) 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US5081127A (en) 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5085992A (en) 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
GB2372114A (en) * 2001-02-07 2002-08-14 Cardionetics Ltd A computerised physical exercise program for rehabilitating cardiac health patients together with remote monitoring
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
ES2646142T3 (es) * 2006-04-24 2017-12-12 Critical Care Diagnostics, Inc. Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2
WO2007143295A2 (en) 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2021796T3 (da) * 2006-05-01 2012-05-29 Critical Care Diagnostics Inc Diagnose af hjerte-kar-sygdom
DK2019965T3 (en) 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
RU2355295C1 (ru) 2007-10-23 2009-05-20 Федеральное Государственное Учреждение "Саратовский Научно-Исследовательский Институт Кардиологии Росмедтехнологий" Способ реабилитации больных ибс
SI2827152T1 (sl) 2008-04-18 2016-10-28 Critical Care Diagnostics,Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
GB0818650D0 (en) * 2008-10-10 2008-11-19 Uni I Oslo Methods
WO2010054810A1 (en) * 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
RU2625014C2 (ru) 2010-04-09 2017-07-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
BR112014016661A8 (pt) 2012-01-04 2017-07-04 Wellesley Pharmaceuticals Llc formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
EP3434260A1 (de) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Verfahren zur behandlung oder vorhersage des risikos des ereignisses von ventrikulärer tachyarrhythmie
RU2019107598A (ru) 2012-08-16 2019-03-28 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
RU2015110054A (ru) 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和系统
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
US9551708B2 (en) 2017-01-24
CN106908604A (zh) 2017-06-30
AU2012284039B2 (en) 2017-03-30
CN106908604B (zh) 2019-01-29
JP2017194469A (ja) 2017-10-26
CN103796669B (zh) 2016-11-09
JP2014529059A (ja) 2014-10-30
US20170122942A1 (en) 2017-05-04
US20130071404A1 (en) 2013-03-21
EP2734222A1 (de) 2014-05-28
AU2012284039A1 (en) 2014-02-06
ES2611403T3 (es) 2017-05-08
EP2734222B1 (de) 2016-10-19
MX2014000715A (es) 2014-02-20
JP6134316B2 (ja) 2017-05-24
US20140286944A1 (en) 2014-09-25
CN103796669A (zh) 2014-05-14
US20190049444A1 (en) 2019-02-14
PL2734222T3 (pl) 2017-03-31
US8748110B2 (en) 2014-06-10
US10928393B2 (en) 2021-02-23
CA2842072A1 (en) 2013-01-24
BR112014001283A2 (pt) 2017-02-21
AU2017204261B2 (en) 2018-09-06
EP3173093B1 (de) 2018-12-05
JP6416974B2 (ja) 2018-10-31
EP3173093A1 (de) 2017-05-31
AU2017204261A1 (en) 2017-07-13
US20210164976A1 (en) 2021-06-03
WO2013012945A1 (en) 2013-01-24
MX351428B (es) 2017-10-13
DK2734222T3 (en) 2017-01-30
EP2734222A4 (de) 2015-04-15

Similar Documents

Publication Publication Date Title
HK1198125A1 (en) Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
IL261768B (en) Devices and methods for tissue treatment
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
ZA201308111B (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
PL2619576T3 (pl) Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy
IL226401A0 (en) Methods for treating disorders related to @fgfBA
HK1201454A1 (en) Therapeutic agents and uses thereof
EP2858517A4 (de) Behandlung und prävention von herz-kreislauf-erkrankungen und thrombose
EP2925312A4 (de) Entacapon zur prävention und behandlung von adipositas und verwandten stoffwechselerkrankungen
IL230433A0 (en) Pain management methods
EP2694079A4 (de) Polymere und verfahren zur schmerzbehandlung
IL232135A0 (en) Therapeutic combinations and methods for treating melanoma
EP2803344A4 (de) Therapeutisches übungsverfahren und therapeutische übungsvorrichtung
HK1212225A1 (en) Therapeutic formulation and methods of treatment
EP2670438A4 (de) Auswahl und behandlung von patienten
EP2575824A4 (de) Verfahren zur behandlung und vorbeugung von entzündungskrankheiten
EP2672965A4 (de) Behandlung und prävention von herz-kreislauf-erkrankungen und thrombose
EP2750508A4 (de) Therapeutische verbindungen und verfahren
EP2710017A4 (de) Makrocyclische therapiemittel und behandlungsverfahren damit
ZA201308176B (en) Therapeutic treatment
GB201113140D0 (en) Prediction and treatment of cancer
IL214194A0 (en) Training and therapy apparatus
GB201115759D0 (en) Therapeutic treatments
GB201115761D0 (en) Therapeutic treatments

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210713